The role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (DOACs)

  • Email
  • Help

Details

TitleThe role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (DOACs)
Date23/11/2015 - 23/11/2015
LocationEuropean Medicines Agency, London, UK
SummaryThis EMA workshop will bring together experts and stakeholders to discuss the utility of pharmacokinetic (PK) and pharmacodynamic (PD) measurements in the clinical use of the new direct oral anticoagulants (DOACs) and whether those could enhance the benefit-risk profile of these medicines by further reducing the risk of major bleedings while maintaining or improving the protection against thromboembolic events. The objectives of the workshop are to improve the understanding of the clinical use of DOACs, issues in relation to PK and PD measurements as well as priorities in future research.

All documents

Name Language First published Last updated
Programme - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (English only) 16/10/2015 17/11/2015
Workshop - the role of pharmacodynamic and pharmacokinetic measurements in the use of direct oral anticoagulants: Background document (English only) 20/11/2015  
Proceedings of the workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (English only) 07/01/2016  
List of participants - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (English only) 07/01/2016  
Presentation - DOACs: the patient perspective (Christine Dehn) (English only) 07/01/2016  
Presentation - Challenging patients on DOACs and need for monitoring (Menno Huisman) (English only) 07/01/2016  
Presentation - Management of DOAC in clinical praxis (Peter J Svensson) (English only) 07/01/2016  
Presentation - What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor (dabigatran etexilate) (Marie Louise S. Christiansen) (English only) 07/01/2016  
Presentation - Session 2: What can we do now and what are the gaps in our knowledge? The direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) (Antonio Gómez-Outes) (English only) 13/01/2016  
Presentation - Session 3: the analytical part - Measuring the concentration of the direct thrombin inhibitor (dabigatran etexilate) (François Mullier) (English only) 07/01/2016  
Presentation - Measuring concentrations of Rivaroxaban, Apixaban, Edoxaban: methods and challenges (Steve Kitchen) (English only) 07/01/2016  
Presentation - NOAC future perspectives: academic perspective (Hugo ten Cate) (English only) 07/01/2016  
Presentation - Future perspectives: how to better use the available data, how to fill the gaps in our knowledge about PK/PD, future ways on how knowledge can be obtained (Jörg Kreuzer) (English only) 07/01/2016  
Presentation - Industry perspective: Bayer/Janssen (Scott D. Berkowitz) (English only) 07/01/2016  
Presentation - Industry perspective: Pfizer - Eliquis® (apixaban) (English only) 07/01/2016  
Presentation - Session 4: future perspectives - What could be done? Industry perspective (Daiichi Sankyo) (English only) 07/01/2016  

Media Videos


Video recording

A video recording is now available.

To view use the ‘Multimedia’ tab.

Related information